Sign inJoin waitlistJoin the waitlist

Clinton Yam

Associate Professor, Breast Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2016–2019
University of Pennsylvania
2013–2016
National University Health System
2008–2013
2009-2011 Medical Officer
2009–2011
Doctor of Medicine
2004–2008

Research

Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer
Journal of Surgical Research · 2010 · First of 8 authors · 126 citations
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Review · The Oncologist · 2017 · First of 3 authors · 77 citations
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Clinical Cancer Research · 2021 · First of 31 authors · 66 citations

Gaiane Rauch
34 papers
Jennifer Litton
31 papers
SM
Stacy Moulder
30 papers
Lei Huo
29 papers
Vicente Valero
29 papers
Beatriz Adrada
25 papers
Rosalind Candelaria
24 papers
Alastair Thompson
23 papers
Banu Arun
19 papers
Wei Yang
16 papers
Naoto Ueno
14 papers
Bora Lim
13 papers

Clinical trials

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2031
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2025–2030
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2026
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2016–2025